Ignis Therapeutics (Suzhou) Limited
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2022-06-28
- Employees
- -
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)
Phase 3
Completed
- Conditions
- Sleep Apnea, ObstructiveExcessive Daytime Sleepiness
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Ignis Therapeutics (Suzhou) Limited
- Target Recruit Count
- 204
- Registration Number
- NCT06103825
- Locations
- 🇨🇳
Shanghai Sixth People's Hospital, ShangHai, Shanghai, China
🇨🇳Beijing TianTan Hospital Capital Medical University, Beijing, China
🇨🇳China-Japan friendship Hospital, Beijing, China
News
No news found